Payment overview · 2025
General Payments
$7,506.54
109 reported records · 22 companies
Healthcare provider profile · identity verified
Simon Yau
Allopathic & Osteopathic Physicians|Internal Medicine|Pulmonary Disease · HOUSTON, TX · NPI 1932494374
Verified facts
What the public records show
CMS Open Payments records show Simon Yau received $7,506.54 in general payments during 2025 across 109 reported records.
Astellas Pharma US Inc accounted for 72.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arikayce, Cresemba, Ofev, Panzyga.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Cresemba as an associated drug or biological on 2800 records involving 1563 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Cresemba by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ofev by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Trelegy Ellipta by this doctor in 2024.
Grifols USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Gamunex-C as an associated drug or biological on 3977 records involving 2134 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Gamunex-C by this doctor in 2024.
Insmed, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Arikayce as an associated drug or biological on 32500 records involving 8305 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Arikayce by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PREVYMIS as an associated drug or biological on 2265 records involving 1245 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Prevymis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 88 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PANZYGA as an associated drug or biological on 8346 records involving 3334 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Panzyga by this doctor in 2024.
Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CUVITRU as an associated drug or biological on 7118 records involving 2610 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Cuvitru by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $5,464.47 | 72.8% | 17 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $300.39 | 4.0% | 15 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $240.52 | 3.2% | 15 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $188.32 | 2.5% | 9 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $144.21 | 1.9% | 5 | 2025 |
| Baxter Healthcare | Unresolved — no canonical attribution shown | $120.34 | 1.6% | 5 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $119.06 | 1.6% | 6 | 2025 |
| Shionogi Inc | Unresolved — no canonical attribution shown | $109.99 | 1.5% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $106.54 | 1.4% | 5 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $90.60 | 1.2% | 3 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $88.13 | 1.2% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.38 | 1.1% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $72.81 | 1.0% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $71.35 | 0.9% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $64.73 | 0.9% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $58.49 | 0.8% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $56.24 | 0.8% | 2 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $32.59 | 0.4% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.48 | 0.4% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.76 | 0.3% | 1 | 2025 |
| INOGEN, INC. | Unresolved — no canonical attribution shown | $20.26 | 0.3% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $16.88 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,860.00 | 2 |
| Food and Beverage | $2,548.51 | 104 |
| Education | $68.99 | 1 |
| Travel and Lodging | $29.04 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Cresemba Normalized: cresemba |
Drug | Astellas Pharma US Inc | $5,395.48 | 16 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $300.39 | 15 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $240.52 | 15 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $188.32 | 9 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $159.27 | 7 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $127.59 | 5 | 2025 |
Source payment records
|
|||||
| Hillrom - Vest System Model 105 Home Care Normalized: hillrom vest system model 105 home care |
Device | Baxter Healthcare | $120.34 | 5 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $119.06 | 6 | 2025 |
Source payment records
|
|||||
| OFEV Normalized: ofev |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $112.06 | 4 | 2025 |
Source payment records
|
|||||
| Fetroja Normalized: fetroja |
Drug | Shionogi Inc | $109.99 | 5 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $106.54 | 5 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $106.54 | 5 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $90.60 | 3 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $88.13 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $85.38 | 3 | 2025 |
Source payment records
|
|||||
| CUTAQUIG Normalized: cutaquig |
Biological | PFIZER INC. | $81.70 | 4 | 2025 |
Source payment records
|
|||||
| REZUROCK Normalized: rezurock |
Drug | SANOFI-AVENTIS U.S. LLC | $72.81 | 1 | 2025 |
Source payment records
|
|||||
| AVYCAZ Normalized: avycaz |
Drug | ABBVIE INC. | $64.73 | 4 | 2025 |
Source payment records
|
|||||
| TEFLARO Normalized: teflaro |
Drug | ABBVIE INC. | $64.73 | 4 | 2025 |
Source payment records
|
|||||
| ARALAST Normalized: aralast |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $58.49 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $32.59 | 1 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $32.59 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $32.15 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $29.48 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $29.05 | 2 | 2025 |
Source payment records
|
|||||
| WINREVAIR Normalized: winrevair |
Biological | Merck Sharp & Dohme LLC | $25.76 | 1 | 2025 |
Source payment records
|
|||||
| INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH Normalized: inogen one g5 oxygen concentrator bluetooth |
Device | INOGEN, INC. | $20.26 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Arikayce arikayce |
2025 | Arikayce | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Cresemba cresemba |
2025 | Cresemba | 2024 | 15 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OFEV ofev |
2025 | Ofev | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| PANZYGA panzyga |
2025 | Panzyga | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Cresemba open payments reported associated product |
CMS Open Payments — General Payments 2800 supporting records · 1563 recipient NPIs · example record 1238560682 |
Cresemba · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Grifols USA, LLC Exact reporting entity; no affiliate inference |
2025 | Gamunex-C open payments reported associated product |
CMS Open Payments — General Payments 3977 supporting records · 2134 recipient NPIs · example record 1249529381 |
Gamunex-C · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Insmed, Inc. Exact reporting entity; no affiliate inference |
2025 | Arikayce open payments reported associated product |
CMS Open Payments — General Payments 32500 supporting records · 8305 recipient NPIs · example record 1186254431 |
Arikayce · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | PREVYMIS open payments reported associated product |
CMS Open Payments — General Payments 2265 supporting records · 1245 recipient NPIs · example record 1237992506 |
Prevymis · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
88 | 32 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PANZYGA open payments reported associated product |
CMS Open Payments — General Payments 8346 supporting records · 3334 recipient NPIs · example record 1228795271 |
Panzyga · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference |
2025 | CUVITRU open payments reported associated product |
CMS Open Payments — General Payments 7118 supporting records · 2610 recipient NPIs · example record 1223616510 |
Cuvitru · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Azithromycin | Azithromycin | 414 | 145 |
| Prednisone | Prednisone | 377 | 141 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 324 | 105 |
| Pantoprazole Sodium | Pantoprazole Sodium | 245 | 80 |
| Tacrolimus | Tacrolimus | 199 | 54 |
| Valganciclovir Hcl | Valganciclovir Hcl | 179 | 57 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 148 | 59 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 52 |
| Montelukast Sodium | Montelukast Sodium | 123 | 46 |
| Metoclopramide Hcl | Metoclopramide Hcl | 91 | 41 |
| Eliquis | Apixaban | 88 | 32 |
| Furosemide | Furosemide | 88 | 37 |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 85 | 27 |
| Famotidine | Famotidine | 80 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 25 |
| Atovaquone | Atovaquone | 73 | 24 |
| Gabapentin | Gabapentin | 60 | 21 |
| Amlodipine Besylate | Amlodipine Besylate | 53 | 24 |
| Mycophenolic Acid | Mycophenolate Sodium | 53 | 20 |
| Voriconazole | Voriconazole | 53 | 17 |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 51 | suppressed |
| Carvedilol | Carvedilol | 50 | 24 |
| Prevymis | Letermovir | 45 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 45 | 19 |
| Posaconazole | Posaconazole | 43 | 13 |
| Dapsone | Dapsone | 41 | 16 |
| Enoxaparin Sodium | Enoxaparin Sodium | 39 | 17 |
| Omeprazole | Omeprazole | 37 | suppressed |
| Itraconazole | Itraconazole | 33 | 11 |
| Levofloxacin | Levofloxacin | 33 | 32 |
| Levothyroxine Sodium | Levothyroxine Sodium | 33 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 31 | 12 |
| Sirolimus | Sirolimus | 31 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 26 |
| Potassium Chloride | Potassium Chloride | 28 | 14 |
| Gammaked | Immune Globul G/Gly/Iga Avg 46 | 27 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 26 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Gammaplex | Immun Glob G(Igg)/Gly/Iga 0-50 | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Envarsus Xr | Tacrolimus | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Ofev | Nintedanib Esylate | 20 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Mirtazapine | Mirtazapine | 19 | 12 |
| Ursodiol | Ursodiol | 18 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 17 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 17 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 15 | suppressed |
| Cresemba | Isavuconazonium Sulfate | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Methylprednisolone Sodium Succ | Methylprednisolone Sod Succ | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Astagraf Xl | Tacrolimus | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Amikacin Sulfate | Amikacin Sulfate | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Cuvitru | Immun Glob G(Igg)/Gly/Iga Ov50 | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Losartan Potassium | Losartan Potassium | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 11 | suppressed |
| Panzyga | Immun Glob G(Igg)-Ifas/Glycine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $7,506.54 · 109 records | Astellas Pharma US Inc | ARALAST, AVYCAZ, Arikayce, CUTAQUIG, Cresemba, DUPIXENT, Fetroja, Flexitouch Plus, Hillrom - Vest System Model 105 Home Care, INOGEN ONE G5 OXYGEN CONCENTRATOR - BLUETOOTH, JASCAYD, MI CANCER SEEK, NUCALA, Nimbl, OCTAGAM IMMUNE GLOBULIN (HUMAN), OFEV, OPSUMIT, OPSYNVI, PANZYGA, PURIFIED CORTROPHIN GEL, Prolastin-C Liquid, REZUROCK, TEFLARO, TEZSPIRE, Tyvaso, UPTRAVI, WINREVAIR, YUPELRI | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arikayce play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error